This Group focuses on treating cancers of the urinary tract and male reproductive system. They are especially concentrated on clinical research for prostate cancer while actively researching on rarer diseases and biomarker-driven research.
PRACTICE CHANGING RESEARCH
Radiation Oncology Group
EORTC 22863 – Phase III randomized clinical trial in high metastatic risk carcinoma of the prostate comparing pelvic radiotherapy plus LHRH analogue.
Jointly with the EORTC Genito-Urinary Cancers Group
EORTC found that combining androgen suppression (during and after) external irradiation improves disease-free and overall survival in patients with locally advanced prostate cancer. This combined treatment approach was the first to show a major improvement in overall survival of patients, making it a gold standard of treatment.
EORTC 30924 – Randomized phase II / III study of high dose intensity M-VAC chemotherapy + G-CSF versus classic M-VAC in advanced urothelial tract tumors.
After a seven-year follow up in patients with advanced urothelial tract cancer, EORTC found that high-dose of the chemotherapy combination (MVAC + G-CSF), provided higher response rates and decreased toxicity in these patients. This became the standard of care.
EORTC 30894 – Phase III study of primary chemotherapy (CMV) in T2G3, T3 and T4a, NO-X, M0 transitional cell carcinoma of the bladder (MRC/EORTC Collaborative Study).
International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now National Cancer Research Institute Bladder Cancer Clinical Studies Group), EORTC GUTCG, the Australian Bladder Cancer Study Group, the NCI of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, & Club Urologico Espanol de Tratamiento Oncologico Group.
This international collaborative study that included EORTC, found that primary chemotherapy (CMV) before secondary treatment, reduced the risk of death by 16% in patients with muscle-invasive urothelial cancer. This was confirmed in a long-term follow up study and changed the standard of care to chemotherapy plus local therapy for invasive bladder cancer.
EORTC 22911 – Phase III study of post-operative external radiotherapy in pathological stage T3N0 prostatic carcinoma.
Joint study of the EORTC Radiotherapy Cooperative Group and the EORTC Genito-Urinary Tract Cancer Cooperative Group
EORTC’s study with a seven-year follow-up in patients with prostate cancer at high risk of progression, confirmed that immediate external irradiation following complete surgical removal of the prostate improves biochemical progression free survival and local control after five years. Exploratory analyses suggested that postoperative irradiation might improve clinical progression free survival in patients younger than 70 years and in those with positive surgical margins, but could have a detrimental effect in patients 70 and older.
EORTC 30985 – Intermittent androgen deprivation in patients with stage D2 prostate cancer-Phase III.
EORTC’s follow-up study of over 13 years in patients treated for metastatic hormone-sensitive prostate cancer, found that intermittent androgen deprivation does not improve overall survival compared to continuous treatment.
EORTC 30962 – Comparative study of intravesical BCG standard dose long-term maintenance versus BCG 1/3 dose long-term maintenance versus BCG standard dose short-term maintenance versus BCG 1/3 dose short-term maintenance in intermediate and high risk Ta- T1 Papillary Carcinoma of the Urinary Bladder.
EORTC study showed that in patients with intermediate and high risk Ta- T1 Papillary Carcinoma of the Urinary Bladder, reducing the the dose or duration of the recommended intravesical immunotherapy treatment (Bacillus Calmette-Guérin (BCG)), does not change its side effects for these patients.
EORTC 30994 – Randomized phase III trial comparing immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4, and/or N+M0 transitional cell carcinoma (TCC) of the bladder.
EORTC’s study comparing two treatment regiments with a seven-year follow-up, in patients with pT3-pT4, and/or N+M0 transitional cell carcinoma (TCC) of the bladder, found that even though immediate chemotherapy did not improve overall survival, it improved progression free survival in these patients.
EORTC 22991 – Three Dimensional Conformal Radiotherapy / Intensity Modulated Radiotherapy alone vs Three Dimensional Conformal Radiotherapy / Intensity Modulated Radiotherapy plus adjuvant hormonal therapy in localized T1b-c, T2a, N0, M0 prostatic carcinoma.
A Phase III Randomized Study.
Thirty percent of patients with high-risk prostate cancer who undergo radiation biochemically, relapse within 5 years. Because prostate cancer is directly linked to androgens, androgen suppression is often another treatment for this disease. This EORTC study investigated whether adding 6 months of androgen suppression after radiation would improve disease-free survival in patients with high-risk prostate cancer. Results showed that, even after a 7 year follow up, radiotherapy plus androgen suppression significantly improved both biochemical and clinical disease-free survival compared to radiotherapy alone.
EORTC 30073 – Randomized Phase III trial comparing immediate versus deferred nephrectomy in patients with synchronous metastatic renal cell carcinoma.
EORTC study compared two treatment regimens in patients with synchronous metastatic renal cell carcinoma. It found that deferring cytoreductive nephrectomy (CN) to after chemotherapy treatment with suntinib, does not improve progression free survival, although overall survival was slightly higher in patients with primary metastatic renal cell carcinoma (mRCC). However, pretreatment with sunitinib may identify patients with inherent resistance to systemic therapy before planned CN.